Last reviewed · How we verify

AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP — Competitive Intelligence Brief

AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP (AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI or NRTI + NNRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NRTI + NNRTI or NRTI + NNRTI) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP (AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP) — SEARCH Research Foundation. These are combination antiretroviral regimens that inhibit HIV reverse transcriptase and protease to suppress viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP TARGET AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP SEARCH Research Foundation phase 3 Antiretroviral combination therapy (NRTI + NNRTI or NRTI + NNRTI) HIV reverse transcriptase, HIV integrase
Atripla or Stribild Atripla or Stribild Fred Hutchinson Cancer Center marketed Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based) HIV reverse transcriptase, HIV integrase
TDF/3TC/EFV or DTG or NVP TDF/3TC/EFV or DTG or NVP MU-JHU CARE marketed Antiretroviral combination therapy (NRTI + NNRTI or INSTI) HIV reverse transcriptase, HIV integrase
efavirenz + emtricitabina + tenofovir efavirenz + emtricitabina + tenofovir Hospital Universitari Vall d'Hebron Research Institute marketed Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) HIV reverse transcriptase, HIV integrase
Atripla (r) Atripla (r) Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections marketed Antiretroviral combination (NNRTI + NRTI + NtRTI) HIV reverse transcriptase, HIV integrase
Multiple Product PrEP Program Multiple Product PrEP Program University of Alabama at Birmingham marketed Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors) HIV reverse transcriptase, HIV integrase
Switch to Triumeq Switch to Triumeq McGill University Health Centre/Research Institute of the McGill University Health Centre marketed Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI or NRTI + NNRTI) class)

  1. SEARCH Research Foundation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP — Competitive Intelligence Brief. https://druglandscape.com/ci/azt-3tc-nvp-azt-d4t-nvp-truvada-nvp. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: